About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Ublituximab + Ibrutinib in Select B-cell Malignancies

NCT02013128·18 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

TG Therapeutics, Inc.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Confirmed Mantle Cell lymphoma (MCL) open for enrollment. The Chronic Lymphocytic Leukemia (CLL) enrollment arm is now closed.
Refractory to or relapsed after at least 1 prior treatment regimen
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

You may not be if

Any major surgery, chemotherapy or immunotherapy within the last 21 days
Known hepatitis B virus, hepatitis C virus or HIV infection
Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded.
Richter's transformation, prolymphocytic leukemia or primary central nervous system lymphoma

The record

StatusCompleted

PhasePhase 1–2

Taking part66

StartedJan 2014

UpdatedOct 24, 2022

Conditions

Chronic Lymphocytic Leukemia Mantle Cell Lymphoma

Where18

TG Therapeutics Investigational Trial Site
Huntsville, Alabama, United States
TG Therapeutics Investigational Trial Site
Tucson, Arizona, United States
TG Therapeutics Investigational Trial Site
Santa Barbara, California, United States

Clareo Health | Ublituximab + Ibrutinib in Select B-cell Malignancies